What is already developed is the antibody. There is no point in trying to create the mRNA version of it before knowing if it even works; we all agree on this. But if the running trials reveal that the antibody actually works, stocks go up, and then there would funding for further developments. There is no need for the company to have experience in the technology as companies partner all the time to exploit their expertise.This is fantasy. They aren't wasting time trialing an antibody to start over with an mRNA drug. This company doesn't even work with mRNA. They don't have the expertise to develop it. They bought the rights to the antibody to commercialize it. There's zero chance they do what you're suggesting. Another company might do it long down the road. Also, 20k is not my estimate. I would estimate between 20-50k. 20k would be very cheap for a mAb.
What I do not know, is wether the license is only about commercialization or they can also make developments upon the antibody itself. If it is just commercialization and exploitation in the current form, then I agree that it is all just fantasy.
